RAND report shows benefit of investment in future health outcomes for adults with Down syndrome
10/1/2024 | For immediate release | Contact: Kate O’Neill ([email protected]) Investment in Alzheimer’s Research Today Will Yield Health Benefits for the Next Generation of Adults With Down Syndrome, New Report […]
Pathways to Parity Program Approved for $250K PCORI Engagement Award
Project will empower advocates, enhance research for people at high risk of Alzheimer’s disease who have Down syndrome Washington, D.C. (Aug. 13, 2024) – The Alliance for Aging Research and […]
FDA issues approval for new Alzheimer’s drug Kisunla; Down syndrome community is optimistic
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and Drug Administration (FDA) announced the approval of Kisunla (donanemab), an […]
Down syndrome population will see a clinical trial of new Alzheimer’s drug
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome will be invited to participate in a clinical trial of […]
MapHabit Study: Assistive Technology Has Positive Outcomes for Children with Down Syndrome
Study Finds Assistive Technology Has Positive Outcomes for Children with Down Syndrome and Their Caregivers In partnership with the LuMind IDSC Foundation (LuMind IDSC), MapHabit, a neuroscience-based assistive technology (AT) […]
Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from accessing new therapies for Alzheimer’s disease, a group of international experts are calling for modification […]
With support from Lilly, LuMind IDSC launches key research and awareness activities to advance Down syndrome research
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research organization, announced a new collaboration with Eli Lilly and Company (Lilly) aimed at accelerating research […]
DS-CTN Data and Safety Monitoring Board (DSMB)
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and Safety Monitoring Board (DSMB). This service was created to provide […]
ANNOUNCEMENT: Richard Fisher Named as Chief Scientific Officer
Date: 7/28/2022
Last week, Richard A. Fisher, Ph.D. joined LuMind IDSC as Chief Scientific Officer. Dr. Fisher’s appointment follows a five-month, international search to fill this leadership role.
“Along with his deep scientific and drug development experience, Rich brings more than 40 years of industry and management knowledge to our organization. I am confident his unique background and skills will elevate and accelerate LuMind IDSC’s research strategy. He will move our mission forward, and we’re lucky to have him on board,” CEO Hampus Hillerstrom said.
Down Syndrome Community Responds to CMS Decision
Date: 4/8/2022
Your advocacy is making a difference! The Down Syndrome Coalition, along with our colleagues from the Down Syndrome Diagnosis Network (DSDN), Down Syndrome Medical Interest Group-USA (DSMIG), International Mosaic Down Syndrome Association (IMDSA), and National Task Group on Intellectual Disabilities and Dementia Practices (NTG), and in partnership with our self-advocates and families, succeeded in removing discriminatory language from an important healthcare coverage determination that would have excluded people with Down syndrome from clinical trials for a new class of Alzheimer’s treatments. Read more…